SCHEMBL4413815

SCHEMBL4413815

O=C(NS(=O)(=O)c1ccc(Cl)s1)c1ccc(-n2c(=O)[nH]c3cc(NCc4ccc(F)cc4)ccc3c2=O)cc1Cl

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RY12 Q9H244 1/20 0.51
HTR3A P46098 2/20 0.37
TP53 P04637 4/20 0.36
MAPT P10636 3/20 0.36
RXFP1 Q9HBX9 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.35
FLT1 P17948 1/20 0.35
FLT4 P35916 1/20 0.35
KDR P35968 1/20 0.35
POLB P06746 2/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
LMNA P02545 1/20 0.34
PDPK1 O15530 1/20 0.33
HPGD P15428 1/20 0.33
PPARG P37231 1/20 0.33
KDM4E B2RXH2 1/20 0.33
PPARA Q07869 1/20 0.33
STING1 Q86WV6 1/20 0.33
CTNNB1 P35222 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4415290 0.94 P2RY12 (0.52) P2RY12HTR3ATP53MAPTRXFP1
SCHEMBL4425407 0.93 P2RY12 (0.51) P2RY12HTR3ATP53MAPTRXFP1
SCHEMBL4415214 0.91 P2RY12 (0.49) P2RY12HTR3ATP53MAPTRXFP1
SCHEMBL4418832 0.90 P2RY12 (0.54) P2RY12HTR3ATP53MAPTRXFP1
SCHEMBL4426718 0.88 P2RY12 (0.49) P2RY12HTR3ATP53MAPTRXFP1
SCHEMBL13635114 0.87 P2RY12 (0.66) P2RY12HTR3ATP53MAPTRXFP1
SCHEMBL4412718 0.87 P2RY12 (0.54) P2RY12HTR3ATP53MAPTRXFP1
SCHEMBL6094405 0.84 P2RY12 (0.59) P2RY12HTR3ATP53MAPTRXFP1
SCHEMBL4412345 0.84 P2RY12 (0.49) P2RY12HTR3ATP53MAPTRXFP1
SCHEMBL13634873 0.83 P2RY12 (0.52) P2RY12TP53MAPTRXFP1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1668002-B1 2,4-DIOXO-3-QUINAZOLINYLARYL SULFONYLUREAS PORTOLA PHARM INC (US) 2009-11-11 EP disclosed
EP-1668002-B1 2,4-DIOXO-3-QUINAZOLINYLARYL SULFONYLUREAS PORTOLA PHARM INC (US) 2009-11-11 EP disclosed
US-7109332-B2 2,4-dioxo-3-quinazolinylaryl sulfonylureas PORTOLA PHARMACEUTICALS, INC. (US) 2006-09-19 US disclosed
US-20050107357-A1 2,4-dioxo-3-quinazolinylaryl sulfonylureas PORTOLA PHARMACEUTICALS, INC. (US) 2005-05-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107357-A1 2,4-dioxo-3-quinazolinylaryl sulfonylureas PFKP, DPP3, P2RY13 P2RY12 21/4885HTR3A 423/4885TP53 3744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.